Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
sc-rAAV2.5IL-1Ra in moderate knee osteoarthritis
NCT02790723Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- Jun 2019
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial of GNSC-001 in osteoarthritis (OA) (3 arms), sponsored by Mayo Clinic. Primary endpoint: Number of subjects experiencing severe adverse events at 53 weeks. Started Jun 2019; status: completed.
02
Drugs
GNSC-001
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02790723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790723.